Department of Pediatrics, University of California San Diego, San Diego, CA, USA.
Division of Allergy, Immunology & Rheumatology, Rady Children's Hospital San Diego, San Diego, CA, USA.
Curr Allergy Asthma Rep. 2024 Apr;24(4):173-197. doi: 10.1007/s11882-024-01132-2. Epub 2024 Mar 5.
The aim of this review is to highlight key published oral immunotherapy (OIT) protocols and post-desensitization strategies for the major food allergens and to cover important concepts to consider when evaluating OIT for food-allergic patients. Shared decision-making should help identify patient and family values which will help influence the type of evidence-based protocol and maintenance strategy to use.
With food OIT emerging as a treatment option, there is a pressing need for patients, physicians, and other providers to have a nuanced understanding of the management choices available to them. There are now randomized controlled trials (RCT) of OIT for peanut, egg, milk, and wheat, and reports of cohorts of patients who have undergone OIT for tree nuts and sesame clinically. The current published protocols contain significant diversity in terms of starting dose, build-up schedule, maintenance dose, and even the product used for desensitization. Emerging data can help direct the long-term maintenance strategy for patients on OIT. Based on patient and family values elicited through the shared decision-making process, an OIT protocol may be selected that balances the level of desensitization, potential side effects, frequency of clinic visits, and potential to induce sustained unresponsiveness, among other factors. Once maintenance dosing is reached, most patients will need to maintain regular exposure to the food allergen to remain desensitized. The option to transition to commercial food products with equivalent amounts of food protein as the OIT maintenance dose would simplify the dosing process and perhaps improve palatability as well. Less frequent or decreased OIT dosing can provide practical benefits but may affect the level of desensitization and safety for some patients.
综述目的: 本文旨在重点介绍主要食物过敏原的口服免疫治疗(OIT)方案和脱敏后策略,并涵盖在评估食物过敏患者的 OIT 时需要考虑的重要概念。共同决策有助于确定患者和家属的价值观,这将有助于影响使用基于证据的方案和维持策略的类型。
最新发现: 随着食物 OIT 作为一种治疗选择的出现,患者、医生和其他提供者迫切需要对他们可用的管理选择有一个细致入微的理解。目前已经有花生、鸡蛋、牛奶和小麦 OIT 的随机对照试验(RCT),以及关于接受坚果和芝麻 OIT 的患者队列的报告。目前发表的方案在起始剂量、递增方案、维持剂量,甚至脱敏用产品方面存在显著差异。新出现的数据可以帮助指导接受 OIT 治疗的患者的长期维持策略。基于通过共同决策过程得出的患者和家庭价值观,可以选择一种 OIT 方案,平衡脱敏水平、潜在副作用、就诊频率以及诱导持续无反应的潜力等因素。一旦达到维持剂量,大多数患者将需要定期接触食物过敏原以保持脱敏状态。过渡到含有与 OIT 维持剂量相当量食物蛋白的商业食品产品的选择将简化给药过程,并可能改善适口性。较少的 OIT 剂量或减少剂量可以带来实际的益处,但可能会影响一些患者的脱敏水平和安全性。